glp-1 obesity drug updates today Chart: 1 in 8 Americans Now Use Drugs for Weight Loss GLP-1 Pipeline Update: August 2025

Increased intakes of fibre and monounsaturated fats (found in olive oil and avocadoes) as well as the time of day when foods are eaten, the order that foods are eaten in, the speed of eating and even chewing can naturally stimulate increased production of the same hormone responsible for the effects of semaglutide drugs

In terms of outcomes, other adverse events (51.5%) were the most prevalent, followed by hospitalization (40.4%), life-threatening (2.8%) and death (2.7%)

Despite premium pricing, Novo has been more effective in negotiating with insurers to improve coverage, making WEGOVY and SAXENDA more accessible to a wider patient base and increasing market share

Metabolic: Euglycemic DKA The risk of euglycemic DKA is very uncommon, but its a clinically important and real complication to be aware of in patients using GLP-1 agonists

Several other small molecules that inhibit DPP-4 have since been developed, such as gemagliptin, anagliptin and teneligliptin

A post-hoc sensitivity analysis excluding ITCA 650 validated the robustness of the pooled hazard ratio (Supplementary Figure D6)